FibroGen (NASDAQ:FGEN) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Thursday.

A number of other equities analysts also recently issued reports on the stock. Jefferies Group reissued a “buy” rating and issued a $75.00 price objective on shares of FibroGen in a report on Tuesday, September 12th. Mizuho reissued a “hold” rating and issued a $61.00 price objective on shares of FibroGen in a report on Thursday, November 9th. Stifel Nicolaus reissued a “buy” rating and issued a $80.00 price objective on shares of FibroGen in a report on Thursday, September 14th. Finally, ValuEngine downgraded shares of FibroGen from a “hold” rating to a “sell” rating in a report on Friday, December 1st. One analyst has rated the stock with a sell rating, three have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $65.67.

FibroGen (NASDAQ:FGEN) opened at $44.55 on Thursday. The company has a current ratio of 10.83, a quick ratio of 10.83 and a debt-to-equity ratio of 0.16. FibroGen has a 1-year low of $19.25 and a 1-year high of $60.15.

In other FibroGen news, CEO Thomas B. Neff sold 18,900 shares of FibroGen stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $54.45, for a total transaction of $1,029,105.00. Following the transaction, the chief executive officer now owns 3,217,455 shares of the company’s stock, valued at $175,190,424.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider K Peony Yu sold 40,000 shares of FibroGen stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $54.63, for a total transaction of $2,185,200.00. The disclosure for this sale can be found here. Insiders have sold 307,710 shares of company stock worth $16,130,149 in the last ninety days. Insiders own 13.60% of the company’s stock.

Large investors have recently modified their holdings of the business. Quantbot Technologies LP bought a new stake in shares of FibroGen during the second quarter valued at approximately $128,000. Ameritas Investment Partners Inc. raised its position in shares of FibroGen by 15.4% during the second quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 696 shares during the last quarter. SG Americas Securities LLC raised its position in shares of FibroGen by 6.5% during the second quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 412 shares during the last quarter. Amalgamated Bank bought a new stake in shares of FibroGen during the second quarter valued at approximately $237,000. Finally, Oppenheimer Asset Management Inc. raised its position in shares of FibroGen by 112.6% during the third quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 2,336 shares during the last quarter. 57.37% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This article was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/12/21/fibrogen-fgen-upgraded-at-bidaskclub.html.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.